CYTR CytRx Corporation

0.56
0  1%
Previous Close 0.55
Open 0.56
Price To Book 0.91
Market Cap 18762998
Shares 33,637,501
Volume 69,033
Short Ratio
Av. Daily Volume 155,037

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 poster at ASCO June 4, 2017. Abstract 11051.
Aldoxorubicin
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Aldoxorubicin
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017 according to 1Q guidance. No mention in 2Q earnings report. MIA.
Aldoxorubicin
Relapsed/refractory small cell lung cancer
Phase 1b dosing initiated February 2018.
Aldoxorubicin
Squamous Cell Carcinoma

Latest News

  1. CytRx Corporation Reports 2018 Financial Results
  2. CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
  3. CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
  4. CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
  5. CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
  6. CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
  7. CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
  8. CytRx Corporation to Present at the 11th Annual LD Micro Main Event
  9. Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
  10. Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT
  11. Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
  12. Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
  13. CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
  14. CytRx: 3Q Earnings Snapshot
  15. CytRx Corporation Reports Third Quarter 2018 Financial Results
  16. Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
  17. CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
  18. Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT
  19. CytRx Corporation to Present at the 2018 MicroCap Conference
  20. CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S